Ventral Hernia Improvement of Treatment and Life
Launched by LINE MARKER · Mar 3, 2025
Trial Information
Current as of November 07, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The VITAL study is a prospective, observational study in Denmark that aims to learn how surgery for ventral hernias (specifically incisional and parastomal hernias) affects a patient’s quality of life. About 300 adults who are referred to the surgical outpatient clinic at Zealand University Hospital will be followed for up to 3 years. Participants may have surgery or be managed with observation, and researchers will track quality of life over time using the Abdominal Hernia-Q questionnaire, along with information on when surgery happens, any postoperative problems, and whether anyone needs emergency surgery while waiting.
If you’re eligible, you must be 18 or older and have an incisional or parastomal hernia, and you must be able to read Danish. The study does not assign treatments; doctors decide whether to operate or observe, and you’ll complete baseline questionnaires plus follow-up questionnaires at 1, 3, 6, 12, and 36 months. The study is currently enrolling and plans to publish results after the 3-year follow-up period.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years
- • Incisional hernia or parastomal hernia
- Exclusion Criteria:
- • - Can't understand or read Danish
About Line Marker
Line Marker is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on precision medicine, Line Marker collaborates with leading researchers and healthcare institutions to accelerate the discovery and delivery of novel therapies. The organization is committed to adhering to the highest ethical standards and regulatory requirements while fostering a patient-centric approach in all its clinical studies. By leveraging cutting-edge technology and data analytics, Line Marker aims to enhance the efficiency and effectiveness of clinical trials, ultimately improving patient outcomes and transforming the landscape of medical treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Køge, Denmark
Patients applied
Trial Officials
Frederik Helgstrand, DMSc
Study Director
Zealand University Hospital, Køge
Line Marker, MD
Principal Investigator
Zealand University Hospital, Køge
Pernille D.K. Diasso, MD, Ph.d.
Study Director
Zealand University Hospital, Køge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported